Product Name :
PF-07238025
CAS No.:
Purity :
Shipping:
Room temperature in the continental U.S. Other areas may vary.
Storage :
Please store the product under the recommended conditions in the Certificate of Analysis.
SMILES:
CC(C)COC(N=C1)=CC=C1C2=NC(C3=CC=CC=C3C(O)=O)=CS2
Product Description :
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation.{{Povorcitinib} medchemexpress|{Povorcitinib} JAK|{Povorcitinib} Technical Information|{Povorcitinib} Data Sheet|{Povorcitinib} custom synthesis|{Povorcitinib} Epigenetics} Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity.{{Ivacaftor} site|{Ivacaftor} Membrane Transporter/Ion Channel|{Ivacaftor} Protocol|{Ivacaftor} Purity|{Ivacaftor} supplier|{Ivacaftor} Cancer} PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice.PMID:22664133
Formula:
C19H18N2O3S
Molecular Weight :
354.42
Synonyms:
Additional Information:
|Formula C19H18N2O3S ; |Molecular Weight 354.42 ; |SMILES CC(C)COC(N=C1)=CC=C1C2=NC(C3=CC=CC=C3C(O)=O)=CS2 ; |Target Endogenous Metabolite ; |Product Description PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice. ; |Shipping Room temperature in the continental U.S. Other areas may vary. ; |Storage Please store the product under the recommended conditions in the Certificate of Analysis.